Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigatars - PubMed (original) (raw)
Clinical Trial
doi: 10.5551/jat.e581. Epub 2008 Dec 11.
Ataru Taniguchi, Kiyoshi Tanaka, Shinji Kagimoto, Yoshio Fujioka, Kenichi Hirata, Yoshio Nakamura, Akane Iwakura, Kyoko Hara, Taizo Yamamoto, Akira Kuroe, Michihiro Ohya, Shimpei Fujimoto, Yoshiyuki Hamamoto, Sachiko Honjo, Hiroki Ikeda, Koichiro Nabe, Kinsuke Tsuda, Nobuya Inagaki, Yutaka Seino, Noriaki Kume; Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology Investigators
Affiliations
- PMID: 19075492
- DOI: 10.5551/jat.e581
Free article
Clinical Trial
Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigatars
Hiroyuki Koshiyama et al. J Atheroscler Thromb. 2008 Dec.
Free article
Abstract
Aim: The effect of pitavastatin on high-sensitivity C-reactive protein (hs-CRP) has not been reported, yet, in humans. We, therefore, investigated the effects of pitavastatin on lipid profiles and hs-CRP in Japanese subjects with hypercholesterolemia.
Methods: The subjects were 178 Japanese with hypercholesterolemia, including 103 (58%) with type 2 diabetes. Pitavastatin (12 mg/day) was administered for 12 months. Serum low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), remnant-like particle cholesterol (RLP-C), triglycerides (TG) and hs-CRP levels were measured for 12 months.
Results: Serum LDL-C and RLP-C levels were significantly decreased by 30.3% and 22.8%, respectively. Serum TG levels were decreased by 15.9% in subjects with basal TG levels above 150 mg/dl. Serum HDL-C levels were significantly increased. The administration of pitavastatin reduced serum hs-CRP levels by 34.8%. No serious adverse events were observed, including changes in glycosylated hemoglobin levels of diabetic patients.
Conclusion: These results suggest that pitavastatin significantly improves lipid profiles and reduces proinflammatory responses, without adverse effects, in Japanese subjects with hypercholesterolemia, including those with diabetes mellitus.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous